Insight

Jordi Remon: Unresolved challenges with ICB and TKIs for early stage NSCLC

Photo taken from Jordi Remon/X

Aug 9, 2024, 14:55

Jordi Remon: Unresolved challenges with ICB and TKIs for early stage NSCLC

Jordi Remon, a Thoracic oncologist at CIOCC Barcelona, recently posted on X:

“In the current landscape treatments for early stage NSCLC several challenges with immunotherapy (ICB) and TKIs remain unresolved.We describe current data and challenges in this setting: role ICB in stage II or PDL1<1%,adjuvant TKI for all?.

Thanks to all authors!”

unresolved

Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies

Autors: Pernelle Lavaud, Martina Bortolot, Lodovica Zullo, David O’Reilly, Jarushka Naidoo, Giannis Mountzios, Olaf Mercier, Lizza E. L. Hendriks, Jordi Remon

unresolved

Source: Jordi Remon/X

cancer David O’Reilly Giannis Mountzios Jarushka Naidoo Jordi Remon Lizza E. L. Hendriks Lodovica Zullo Martina Bortolot Olaf Mercier OncoDaily Oncology Pernelle Lavaud

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage